At a glance
ClinicalIndex Comparison RecordN/ACompleted· 39 enrolled
Drug / intervention
Ezetimibe 10 mg +1 moredrug
Likely dose
Ezetimibe 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Evaluation of LDL Levels in Patients Converted From Zetia (Ezetimibe)10 mg to 5 mg
In Brief
A clinical study evaluating Ezetimibe 10 mg and Ezetimibe 5 mg for Hypercholesterolemia. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
Primary CompletionSep 2008
First PostedSep 2008
TodayJul 2026
First PostedSep 30, 2008
Enrollment StartJul 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.8 years ago
Interventions
Ezetimibe 10 mgdrug
Ezetimibe 10 mg daily for 4 weeks
Ezetimibe 5 mgdrug
Ezetimibe 5 mg daily for 4 weeks, "formulated" as a 10 mg tablet split in half